• All Courts
  • Federal Courts
  • Bankruptcies
  • PTAB
  • ITC
Track Search
Export
Download All
Displaying 84-98 of 311 results

1016 Exhibit: Kee et al, US Patent No 5,369,095, Compositions And Method Comprising Substituted Glycosides As Mucus Membrane Permeation Enhancers, issued November 29, 1994 Kee

Document IPR2019-00451, No. 1016-32 Exhibit - Kee et al, US Patent No 5,369,095, Compositions And Method Comprising Substituted Glycosides As Mucus Membrane Permeation Enhancers, issued No...
How ever, the treatment of conditions involving physiolog ical mechanisms within the eye (e. g., glaucoma, diabetic retinopathy, cataracts, etc.) generally does require the permeation of topically applied ophthalmic drugs pri marily through the cornea.
It has been reported that benzalkonium chloride (BAC), bile salts, dimethyl sulfoxide (DMSO), ethylenediamine tetraace tate (EDTA) and l-dodecylazayl-cycloheptan-2-one (AZONE ®) enhance the corneal penetration of cer tain drugs.
A principal objective of the present invention is to provide for a method of enhancing drug delivery across mucus covered epithelial tissues, particularly those of the cornea, sclera and conjunctiva of humans and ani mals.
Higher order saccharides being covalently linked in any of a number of ways to form different isomeric structures include for example disaccharides such as maltose, cellobiose, sucrose and lactose and trisaccharides, such as raffmose.
The method of claim 6 wherein the composition comprises a viscosity enhancing polymer selected from the group consisting of: alginates, carrageenan, gar, karaya, locust beans, tragacanth, zanthan, carbomer, hydroxyethylcellulose, hydroxypropylcelluiose, hy droxypropylmethylcellulose, methylcellulose, polyvi nyl alcohol, polyvinyl pyrrolidone, carboxymethylcel lulose and agarose.
cite Cite Document

1043 Exhibit: Knoester, et al, Pharmacokinetics and pharmacodynamics of midazolam administered as a concentrated intranasal spray A study in healthy volunteers, Br J Clin Pharmacol 2002 May535501 7

Document IPR2019-00451, No. 1043-61 Exhibit - Knoester, et al, Pharmacokinetics and pharmacodynamics of midazolam administered as a concentrated intranasal spray A study in healthy volunteers, Br...
None had a history of cardiac or neurological disease.
The symptoms disappeared within 10 min in all but one subject, in whom intranasal irritation lasted for 25 min All subjects tolerated intranasal administration well and none found it to be painful.
cite Cite Document

1007 Exhibit: Part 7 ¿¿¿ Pages 2401 2800 File History for Non Provisional Patent Application Serial No 12413,439, filed March 27, 2009 ¿¿¿439 FH

Document IPR2019-00451, No. 1007-21 Exhibit - Part 7 ¿¿¿ Pages 2401 2800 File History for Non Provisional Patent Application Serial No 12413,439, filed March 27, 2009 ¿¿¿439 FH (P.T.A.B. Jan. 29, 2019...
Nonetheless. for ophthalmic uses, the previously described polymer concentration ranges are preferred.
Although many attempts have been made to safely and efficiently administer insulin, heparin and other macromolecular drugs by non- injectable routes, none have proved successful, and it has become apparent that the success of such ...
None of the six volunteers had local irritation of the nostrils 30 minutes after application, see table 2.
Visual inspection of the appearance of the spray plume of three solutions in the viscosity range from 5.8 to 41.7 revealed that a plume was formed and none of them “squirted.” [00262] These results demonstrated that at 20-25°C all ...
cite Cite Document
+ More Snippets

1049 Exhibit: Cartt¿¿¿784 Assignment, dated March 6, 2012, recorded March 29, 2012 Cartt¿¿¿784 Assignment

Document IPR2019-00451, No. 1049-67 Exhibit - Cartt¿¿¿784 Assignment, dated March 6, 2012, recorded March 29, 2012 Cartt¿¿¿784 Assignment (P.T.A.B. Jan. 29, 2019)
Edward T. Maggio 16870 W. Bernardo Drive Suite 390 San Diego, CA 92127 (hereinafter “Inventor(s)),” have invented certain new and useful improvements in Multimodal Particulate Formulations X for which Application No. 12/1 16 842 was filed on May 7, 2008 in the United States Patent Office; WHEREAS, Aegis Therapeutics, LLC, a limited liability company of the State of California, having a place of business at 16870 W. Bernardo Drive Suite 390, San Diego, CA 92127, (hereinafter “Assignee”), is desirous of acquiring the entire right, title and interest in and to said Application(s) and the inventions disclosed therein, and in and to all embodiments of the inventions, heretofore conceived, made or discovered, whether jointly or severally, by said lnventor(s) (hereinafter collectively referred to as “Inventions”), and in and to any and all patents, inventor's certificates and other forms of protection (hereinafter “Patent(s)”) thereon granted in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty.
NOW, THEREFORE, in consideration of good and valuable consideration acknowledged by said lnventor(s) to have been received in full from said Assignee: Said lnventor(s) do hereby sell, assign, transfer and convey unto said Assignee the entire right, title and interest (a) in
fullest extent the right, title and interest herein conveyed in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty.
Such cooperation by said lnventor(s) shall include prompt production of pertinent facts and documents, giving of testimony, execution of petitions, oaths, specifications, declarations or other papers, and other assistance all to the extent deemed necessary or desirable by said Assignee (a) for perfecting in said Assignee the right, title and interest herein conveyed; (b) for prosecuting any applications covering said Inventions; (c) for filing and prosecuting substitute, divisional, continuing or additional applications covering said Inventions; (d) for filing and prosecuting applications for reissuance of any said Patent(s); (e) for interference or other priority proceedings involving said Inventions; and (f) for legal proceedings involving said Inventions and any applications therefor and any Patent(s) granted thereon, including without limitation reissues and reexaminations, opposition proceedings, cancellation proceedings, priority contests, public use proceedings, infringement actions and court actions; provided, however, that the expense incurred by said lnventor(s) in providing such cooperation shall be paid for by said Assignee.
‘ Docket Number 35401-714201 IN WITNESS WHEREOF said Inventor(s) have executed and delivered this instrument to said Assignee as of the dates written Bygflb'; (fir; _'
cite Cite Document

1022 Exhibit: Liversidge et al, US Patent Application Publication No US 200601988...

Document IPR2019-00451, No. 1022-38 Exhibit - Liversidge et al, US Patent Application Publication No US 20060198896, Serial No 11354,249, published September 7, 2006 Liversidge (P.T.A.B. Jan. 29, ...

cite Cite Document

1040 Exhibit: Part 1 Pages 1 250 File History for EP 128 013729, based on WO 201...

Document IPR2019-00451, No. 1040-56 Exhibit - Part 1 Pages 1 250 File History for EP 128 013729, based on WO 2012174158 and PCTUS2012042311 (P.T.A.B. Jan. 29, 2019)

cite Cite Document

1032 Exhibit: Edman II et al, Microspheres as a nasal delivery system for peptide d...

Document IPR2019-00451, No. 1032-48 Exhibit - Edman II et al, Microspheres as a nasal delivery system for peptide drugs, Journal of Controlled Release, Vol 21 1992 165 l72 Edman II (P.T.A.B. Jan. 29, 2...

cite Cite Document

1031 Exhibit: Rowe et al, editors, Handbook of Pharmaceutical Excipients, Fourth E...

Document IPR2019-00451, No. 1031-47 Exhibit - Rowe et al, editors, Handbook of Pharmaceutical Excipients, Fourth Edition 2003, Monographs, American Pharmaceutical Association, Washington DC Row...

cite Cite Document

1036 Exhibit: Deshmukh et al, Lorazepam in the Treatment of Refractory Neonatal ...

Document IPR2019-00451, No. 1036-52 Exhibit - Deshmukh et al, Lorazepam in the Treatment of Refractory Neonatal Seizures, Am J Dis Child 1986140101042 1044 Deshmukh (P.T.A.B. Jan. 29, 2019)

cite Cite Document

1002 Exhibit: Part 1 Pages 1 270 File History for ¿¿¿876 Patent, Ser No 14527,613 ¿¿...

Document IPR2019-00451, No. 1002-2 Exhibit - Part 1 Pages 1 270 File History for ¿¿¿876 Patent, Ser No 14527,613 ¿¿¿876 FH (P.T.A.B. Jan. 29, 2019)

cite Cite Document

1010 Exhibit: US Patent Application Publication No US 20090258865, Administratio...

Document IPR2019-00451, No. 1010-26 Exhibit - US Patent Application Publication No US 20090258865, Administration of Benzodiazepine Compositions, Serial No 12413,439 Cartt¿¿¿865 (P.T.A.B. Jan. 2...

cite Cite Document

1015 Exhibit: Cartt et al, US Patent Application Publication No US 20080279784, N...

Document IPR2019-00451, No. 1015-31 Exhibit - Cartt et al, US Patent Application Publication No US 20080279784, Nasal Administration Of Benzodiazepines, Serial No 12116,842, published November 1...

cite Cite Document

1014 Exhibit: Gwozdz et al, WO 2009120933, Pharmaceutical Solutions And Metho...

Document IPR2019-00451, No. 1014-30 Exhibit - Gwozdz et al, WO 2009120933, Pharmaceutical Solutions And Method For Solubilizing Therapeutic Agents, published October 1, 2009, International Filing...

cite Cite Document

1002 Exhibit: Part 2 Pages 271 530 File History for ¿¿¿876 Patent, Ser No 14527,613...

Document IPR2019-00451, No. 1002-3 Exhibit - Part 2 Pages 271 530 File History for ¿¿¿876 Patent, Ser No 14527,613 ¿¿¿876 FH (P.T.A.B. Jan. 29, 2019)

cite Cite Document

1004 Exhibit: Part 4 ¿¿¿ Pages 1051 1400 File History for ¿¿¿546 Patent, Ser No 1349...

Document IPR2019-00451, No. 1004-8 Exhibit - Part 4 ¿¿¿ Pages 1051 1400 File History for ¿¿¿546 Patent, Ser No 13495,942 ¿¿¿546 FH (P.T.A.B. Jan. 29, 2019)

cite Cite Document
<< 1 2 3 4 5 6 7 8 9 10 ... >>